Synendos Therapeutics AG (“Synendos”), a Swiss a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS) disorders, closed its Series A financing round, raising CHF 20m. The financing was co-led by Kurma Partners and Sunstone Life Science Ventures with participation from BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private Investors. Synendos will use the funds primarily to advance its research in the development of treatments of Central Nervous System disorders.
VISCHER advised Synendos on all legal issues related to the transaction. The VISCHER team included Christian Wyss (Partner, Corporate / M&A), Luzius Zumstein (Senior Associate, Corporate / M&A) and Dario Glauser (Junior Associate, Corporate / M&A).